A single wallet withdrew 16,976 SOL (about $1.76 million) from Binance and used it to buy 9.32 million STONK tokens at $0.19 during a 33% price dip. Despite buying during a decline, STONK surged to a new all-time high of $0.2234 the same day, up nearly 50% in 24 hours and over 1,100% in a week. STONK is the native token of Stonkfun, a Solana-based launchpad that pairs new tokens with tokenized equities rather than just SOL or stablecoins. The platform recently generated $1.5 million in daily revenue, funding buybacks that support STONK's price. This surge reflects speculative capital moving into high-volume, buyback-supported tokens amid stable major cryptocurrencies.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
